Top Markets
#1 Islamic Coin Islamic Coin +151.57%
#2 Fake World Assets Fake World Assets +29.88%
#3 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.39%
#4 Not in Employment, Education, or Training Not in Employment, Education, or Training +16.38%
#5 Palladium Network Palladium Network +12.71%
#6 clBTC clBTC +12.14%
#7 Akedo Akedo +11.89%
#8 TENDIES TENDIES +10.53%
#9 Pons Pons +10.38%
#10 Pieverse Pieverse +8.97%
Coin of the day
Islamic Coin Islamic Coin
設定
言語
日本
通貨
USD
テーマ
Cyxone AB (publ) Cyxone AB (publ)

Cyxone AB (publ)

CYXO
株式のランク #40403
Cyxone AB (publ) is a clinical-stage biotechnology firm focused on developing... Cyxone AB (publ) is a clinical-stage biotechnology firm focused on developing innovative, disease-modifying therapies. Its primary therapeutic targets include rheumatoid arthritis, multiple sclerosis, and acute respiratory illnesses caused by viruses. The company's pipeline features Rabeximod, currently in Phase II clinical trials for both rheumatoid arthritis and COVID-19. Additionally, T20K, a drug candidate for multiple sclerosis, is undergoing Phase 1 evaluation. Established in 2015, the company is headquartered in Malmö, Sweden.
株価
$0.00162013
最終同期: 2025-01-03
時価総額
$156.25K
変化（1日）
0.36%
変化（1年）
0.00%
国
SE
取引 Cyxone AB (publ) (CYXO)

カテゴリー

Healthcare
Cyxone AB (publ)（CYXO）のP/B比率
August 2026 時点のP/B比率 TTM: 0.05
Cyxone AB (publ) の最新の財務報告および株価によると、現在のP/B比率（TTM）は 0.05 です。2022 年末時点でのP/B比率は 0.95 でした。
Cyxone AB (publ) の P/B 比率の履歴（2015 ～ 2026）
各年末時点のP/B比率
年 P/B比率 変化
2026 (TTM) 0.05 -80.68%
2023 0.25 -73.81%
2022 0.95 -62.04%
2021 2.50 -27.47%
2020 3.45 49.69%
2019 2.31 74.16%
2018 1.32 -75.84%
2017 5.48 22.16%
2016 4.49 -98.16%
2015 243.41 0.00%
同業他社のP/B比率
企業 P/B比率 P/B比率の差 国
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.2613 12,863.35%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.3483 13,043.48%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 3.634 7,423.81%
BE